Literature DB >> 12811229

Potential role of increased iron stores in diabetes.

James G Wilson1, Jennifer Hoff Lindquist, Steven C Grambow, Errol D Crook, Joseph F Maher.   

Abstract

Diabetes mellitus (DM) is an important risk factor for the development of cardiovascular disease. Extensive clinical, epidemiologic, and basic studies suggest that excessive tissue iron stores may contribute to the occurrence and complications of DM. Secondary diabetes occurs in inherited pathologic iron overload syndromes of European- and African-derived populations and is an established complication of transfusional iron overload. Epidemiologic studies have repeatedly shown positive correlation between levels of serum ferritin and those of fasting glucose, insulin, and glycosylated hemoglobin. Iron reduction therapy in hereditary hemochromatosis and transfusional iron overload is associated with improved glucose tolerance and reduced incidence of secondary diabetes. Trials of iron reduction therapy in diabetes mellitus, although limited and inconclusive, have shown clinical improvement in some patients. The current article reviews evidence suggesting that tissue iron contributes to DM and its complications and presents preliminary data that emphasize the potential importance of iron overload in DM of African Americans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12811229     DOI: 10.1097/00000441-200306000-00004

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  47 in total

1.  A meat, processed meat, and French fries dietary pattern is associated with high allostatic load in Puerto Rican older adults.

Authors:  Josiemer Mattei; Sabrina E Noel; Katherine L Tucker
Journal:  J Am Diet Assoc       Date:  2011-10

Review 2.  Diabetes and hemochromatosis.

Authors:  T Creighton Mitchell; Donald A McClain
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

3.  Iron and glucose homeostasis: new lessons from hereditary haemochromatosis.

Authors:  J G Wilson
Journal:  Diabetologia       Date:  2006-07       Impact factor: 10.122

4.  Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep-/-) mouse.

Authors:  Robert C Cooksey; Deborah Jones; Scott Gabrielsen; Jingyu Huang; Judith A Simcox; Bai Luo; Yudi Soesanto; Hugh Rienhoff; E Dale Abel; Donald A McClain
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-03-30       Impact factor: 4.310

Review 5.  Iron and diabetes risk.

Authors:  Judith A Simcox; Donald A McClain
Journal:  Cell Metab       Date:  2013-03-05       Impact factor: 27.287

6.  Anthropometric indices added the predictive ability of iron status in prognosis of atherosclerosis.

Authors:  Motahar Heidari-Beni; Mehrangiz Ebrahimi-Mameghani; Masoud Hajimaghsood; Mohammad Asghari Jafarabadi
Journal:  Health Promot Perspect       Date:  2012-12-28

7.  Adipose Tissue Transferrin and Insulin Resistance.

Authors:  Donald A McClain; Neeraj K Sharma; Shalini Jain; Alexandria Harrison; Lipika N Salaye; Mary E Comeau; Carl D Langefeld; Felipe R Lorenzo; Swapan K Das
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

8.  Effects of Cardiorespiratory Fitness on Serum Ferritin Concentration and Incidence of Type 2 Diabetes: Evidence from the Aerobics Center Longitudinal Study (ACLS).

Authors:  Tuan D Le; Sejong Bae; Chiehwen Ed Hsu; Karan P Singh; Steven N Blair; Ning Shang
Journal:  Rev Diabet Stud       Date:  2009-02-10

9.  High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis.

Authors:  D A McClain; D Abraham; J Rogers; R Brady; P Gault; R Ajioka; J P Kushner
Journal:  Diabetologia       Date:  2006-03-15       Impact factor: 10.122

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.